Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 4/20 | 1.00 |
| ▸ | CA2 | P00918 | 15/20 | 0.55 |
| ▸ | CA1 | P00915 | 11/20 | 0.55 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 7/20 | 0.52 |
| ▸ | CA12 | O43570 | 6/20 | 0.52 |
| ▸ | CA7 | P43166 | 5/20 | 0.52 |
| ▸ | CA4 | P22748 | 4/20 | 0.52 |
| ▸ | CA6 | P23280 | 4/20 | 0.52 |
| ▸ | CA5A | P35218 | 4/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.52 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12867054 | 0.82 | MIF (0.70) | MIFCA2CA1TRPA1CA9 | |
| SCHEMBL13123444 | 0.81 | MIF (0.69) | MIFTRPA1ALDH1A1CYP3A4HPGD | |
| SCHEMBL28839087 | 0.80 | MIF (0.66) | MIFCA2CA1CA9CA12 | |
| SCHEMBL2141861 | 0.79 | MIF (0.77) | MIFTRPA1ALDH1A1CYP3A4HPGD | |
| SCHEMBL13667799 | 0.79 | MIF (0.65) | MIFCA2CA1CA9CA12 | |
| SCHEMBL3665119 | 0.76 | MIF (0.61) | MIFCA2CA1CA9CA12 | |
| SCHEMBL28839002 | 0.74 | MIF (0.58) | MIFCA2CA1CA9CA12 | |
| SCHEMBL28839005 | 0.74 | MIF (0.58) | MIFCA2CA1CA9CA12 | |
| SCHEMBL8763362 | 0.73 | MIF (0.68) | MIFTRPA1ALDH1A1CYP3A4HPGD | |
| SCHEMBL8000894 | 0.72 | CA2 (0.67) | MIFCA2CA1CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2823826-A2 | Inhibitors of carbonic anhydrase IX | Molecular Insight Pharmaceuticals, Inc. (US) | 2015-01-14 | — | — | EP | disclosed |
| US-8877970-B2 | Inhibitors of carbonic anhydrase IX | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-8877970-B2 | Inhibitors of carbonic anhydrase IX | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-8877970-B2 | Inhibitors of carbonic anhydrase IX | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| EP-2240171-A2 | INHIBITORS OF CARBONIC ANHYDRASE IX | Molecular Insight Pharmaceuticals, Inc. (US) | 2010-10-20 | — | — | EP | disclosed |
| US-20090270372-A1 | NOVEL DERIVATIVES OF BENZIMIDAZOLE AND IMIDAZO-PYRIDINE AND THEIR USE AS MEDICAMENTS | SOCIETE DE CONSEILS DE RECHERCHES ET (FR) | 2009-10-29 | — | — | US | disclosed |
| WO-2009089383-A2 | INHIBITORS OF CARBONIC ANHYDRASE IX | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| US-20090175794-A1 | INHIBITORS OF CARBONIC ANHYDRASE IX | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2009-07-09 | — | — | US | disclosed |
| US-20090175794-A1 | INHIBITORS OF CARBONIC ANHYDRASE IX | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2009-07-09 | — | — | US | disclosed |
| US-20090175794-A1 | INHIBITORS OF CARBONIC ANHYDRASE IX | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2009-07-09 | — | — | US | disclosed |
| EP-1421935-A1 | Thiourea carbonic anhydrase inhibitors and their use in treatment of glaucoma | Casini, Angela (IT) | 2004-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270372-A1 | NOVEL DERIVATIVES OF BENZIMIDAZOLE AND IMIDAZO-PYRIDINE AND THEIR USE AS MEDICAMENTS | MC4R, MC3R, MC1R | MIF 277/4885CA2 2160/4885CA1 4782/4885 |
| US-20090175794-A1 | INHIBITORS OF CARBONIC ANHYDRASE IX | CA9, CA12, CA1 | MIF 4374/4885CA2 7/4885CA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.